A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KER-047 Administered to Healthy Male Volunteers and Postmenopausal Female Volunteers
Randomized, Double-Blind, Placebo-Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-050 Administered to Healthy, Postmenopausal Women.
100 Clinical Results associated with Keros Therapeutics Australia Pty Ltd.
0 Patents (Medical) associated with Keros Therapeutics Australia Pty Ltd.
100 Deals associated with Keros Therapeutics Australia Pty Ltd.
100 Translational Medicine associated with Keros Therapeutics Australia Pty Ltd.